logo
  

SNC-Lavalin Group Q1 Results To Estimates - Quick Facts

SNC-Lavalin Group Inc. (SNC.TO) reported a first-quarter net income attributable to shareholders of C$73.05 million, compared to a net loss of C$65.96 million in the prior-year quarter.

Net income from continuing operations was C$67.74 million or C$0.39 per share, sharply higher than C$1.0 million or C$0.01 per share in the year-ago quarter. Adjusted net income was C$0.51 per share, compared to last year's C$0.52 per share.

Total revenues for the quarter edged down to C$1.82 billion from C$1.87 billion in the same quarter last year.

On average, analysts polled by Thomson Reuters expected the company to report earnings of C$0.37 per share on revenues of C$1.74 billion for the quarter. Analysts' estimates typically exclude special items.

The company's Board of Directors also declared a cash dividend of $0.02 per share, unchanged from the previous quarter, payable on June 11, 2021, to shareholders of record on May 28, 2021.

Looking ahead to fiscal 2021, the company continues to expect SNCL Engineering Services revenue to grow by a low single digit percentage from last year and segment adjusted EBIT as a percentage of revenue of 8 to 10 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The 737 MAX 10, Boeing Co.'s largest 737 Max model, is taking its maiden flight today, reports said citing people familiar with the matter. The flight after months of testing and certification will be around 10 a.m. local time from the Seattle area. The schedule could change depending on weather or other factors. Meanwhile, the jetliner is expected to enter commercial service in 2023. Medical devices supplier Smiths Medical, affiliated to Smiths Group plc, is recalling certain Jelco Hypodermic Needle-Pro Fixed Needle insulin syringes with skewed graduation markings, the U.S. Food and Drug Administration said. The recall was initiated after the company became aware of specific models and lots of Jelco insulin syringes that may exhibit skewed odd number line graduation markings. Saliva-based COVID-19 testing is rolled out as a pilot for public schools in New York City. The new two-month pilot program is being implemented in about 50 New York City public schools and utilizes Fluidigm Technology to offer RT-PCR COVID-19 testing. New York City public schools have instituted mandatory random weekly testing in all reopened school buildings to ensure safer in-person learning.
RELATED NEWS
Follow RTT